BioSpace News Archive

Merck (NYSE: MRK) today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma.

Antengene Corporation Limited (“Antengene” SEHK: 6996.HK) is presenting encouraging clinical data of the Company’s four key drugs in clinical development: ATG-101 (PD-L1/4-1BB bispecific antibody), ATG-022 (Claudin 18.2 antibody-drug conjugate), ATG-037 (oral CD73 inhibitor), and ATG-008 (dual mTORC1/2 inhibitor), at its 2023 R&D Day taking place today.

Astellas Pharma Inc. and Pfizer Inc. announced that the companies received an approval by the U.S. Food and Drug Administration of a supplemental New Drug Application for XTANDI®, following FDA expedited development and review programs, based on results from the Phase 3 EMBARK trial.

Poolbeg Pharma announces that an abstract highlighting the potential of POLB 001 as a groundbreaking therapy has been accepted for presentation at the 18th International Congress of Immunology, to be held 27 November - 2 December 2023 in Cape Town, South Africa.

SciBase Holding AB, a leading developer of augmented intelligence-based solutions for skin disorders announced that they have entered into a collaboration agreement with the Skin and Cancer Institute to pilot Nevisense in several of their California locations.

Stevanato Group announced that its Mavis™ Combi visual inspection machine has been selected as a winner of the 2023 Pharma Innovation Awards by Pharma Manufacturing, a brand of Endeavor Business Media.

LAVA Therapeutics N.V. announced recent corporate highlights and financial results for the quarter ended September 30, 2023.

ADMA Biologics, Inc. announced that it has received U.S. Food and Drug Administration approval for its tenth ADMA BioCenters plasma collection facility located in Laurel, Maryland.

Bioretec Ltd, a pioneer of biodegradable orthopedic implants, is initiating a new CEO recruitment process as the company’s current CEO, Mr. Timo Lehtonen, shall transfer into a new role within the company.

Chemomab Therapeutics Ltd. reported on its poster presentation at the American College of Rheumatology Convergence 2023 conference.